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Abstract: Osmotic demyelination syndrome (ODS) is a disorder of the central myelin that is often
associated with a precipitous rise of serum sodium. Remarkably, while the myelin and oligodendrocytes
of specific brain areas degenerate during the disease, neighboring neurons and axons appear unspoiled,
and neuroinflammation appears only once demyelination is well established. In addition to blood-brain
barrier breakdown and microglia activation, astrocyte death is among one of the earliest events during
ODS pathology. This review will focus on various aspects of biochemical, molecular and cellular aspects
of oligodendrocyte and astrocyte changes in ODS-susceptible brain regions, with an emphasis on the
crosstalk between those two glial cells. Emerging evidence pointing to the initiating role of astrocytes
in region-specific degeneration are discussed.
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1. Introduction
Osmotic demyelination syndrome encompasses a broad symptomatology from disorientation,
slight confusion, paresis and memory loss to seizure, unresponsiveness and coma, depending on the
degree of myelin loss in the pons and the presence of extrapontine lesions [1–3]. This clinical picture
is often linked with an abrupt variation of plasma osmolality, although a variety of cases have now
been reported independently of any electrolyte disturbances (alcoholism, malnutrition, cirrhosis, liver
transplantation, AIDS, folate deficiency, hyperglycemic states) [4]. Most of the cases are iatrogenic and
occur when, in a context of a chronic (>48 h) and profound (<120 mEq/L) hyponatremia, low serum
sodium levels are quickly corrected using an abrupt NaCl gradient in an attempt to reach normal
ranges of natremia. In the first autopsy reports described in 1959, demyelinated areas were identified in
the centro-pontine region as symmetric, sharply outlined lesions confined to the center of the median
raphe, and hence led to the seminal appellation of “central pontine myelinolysis” [5]. The lesion
seemed to spread out from the midline area of the basis pontis with relative sparing of the adjacent
corticospinal and corticobulbar tracts. Extensions to the tegmentum and mesencephalon were observed
in some of the largest lesions. In a retrospective and systematic examination of 58 cases, central pontine
myelinolysis was combined with extra-pontine involvement in 31% of the cases [6]. The cerebellum,
lateral geniculate body, thalami, basal ganglia, subcortical white matter and midbrain structures
are the most frequently affected extra-pontine regions and, from a cytoarchitectonic point-of-view,
contain a rich apposition of gray and white matter [7]. Singularly, the highly myelinated fibers
such as those of the corpus callosum or the anterior commissure are spared from any demyelination.
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Macroscopic analysis of first autopsy cases identified triangular, T-, bat- or diamond-shaped areas of
discoloration in the basis pontis. Microscopic analysis revealed in the pre-identified lesions striking
myelin abnormalities including swollen myelin sheaths, myelin fragmentation and demyelinated
fiber bundles with concomitant loss of oligodendrocytes, and, if these cells were still found, they
were shrunken, damaged or even necrotic [5,8]. Nerve cells and axis cylinders within the lesion
were relatively well preserved. As human samples of pons were often analyzed at advanced stages
of the disease, neuroinflammation was prominent, in the form of activated microglia and myelin
debris scavenged by these macrophages. Peri-lesional astrocytes were hypertrophied and, in old
lesions, there could be a central area of cavitation. Due to the highly specific and reproducible
location of the demyelinating lesions, the authors who described the seminal case series named the
disease “central pontine myelinolysis.” At that time, the term “demyelination” was avoided in order
to distinguish this condition, wherein myelin loss appears independently of inflammation, from the
multifocal perivascular lymphocytic infiltrates found in multiple sclerosis. It was only later that
“osmotic demyelination syndrome” was adopted, gathering both centropontine and extrapontine
manifestations in a same pathological entity.
2. First Proposed Etiologic Mechanisms
As the centropontine lesions were symmetrical and constant in location, with a sudden onset of
symptoms, the syndrome was first proposed as having a toxic or metabolic etiology. In his report,
Adams and colleagues concluded in favor of an exogenous or endogenous intoxication, or some
deficiency of essential substance to the metabolism of nervous cells [5]. Autopsy examination in the
pons of CPM cases revealed large areas of yellowish or greenish discoloration, suggesting red blood
cells and hemoglobin degradation subsequent to blood-brain barrier breakdown. Damage to myelin
sheaths and oligodendrocytes was therefore explained by exposure of nerve tissue to unidentified
blood-borne component(s) endowed with myelinolytic properties. Rapidly, the question arose as
to why some CNS regions were more vulnerable to demyelination than others. The anatomical
architecture of the basis pons is singular in that gray matter and white matter are intermixed in
such a way that white matter-embedded oligodendrocytes are in close proximity to capillary rich
gray matter, making them more exposed to osmotic variation and extravasated blood components.
While blood-brain barrier (BBB) disruption with extravasated red blood cells and blood proteins
has been demonstrated in ODS patients and experimental models, the link to oligodendrocyte
loss and the time it occurs are still elusive. Intriguingly, the neuron cell bodies and neurites are
spared as well as the endothelial cells showing undisturbed tight junctions and barely mild swollen
intracellular organelles. Although the mechanism of injury is not clearly defined, both clinical and
animal studies support the central role of osmotic stress, most commonly due to a rapid correction
of chronic hyponatremia. For a long time, the role of sodium has been underappreciated because
in the early years of internal medicine (1960–1970), serum electrolytes were not routinely measured.
In the seminal case of Adams et al., hypokaliemia was suspected because of the electrocardiogram
abnormalities [5]. Nevertheless, the correction of the confirmed hypokalemia did not modify the
neurological manifestations of the patient.
3. The Electrolyte Disturbance Hypothesis and Lessons from Experimental Models
Although Adams and others described the first cases of CPM in humans without identifying the
cause of demyelination, an earlier report released in 1923 by Rowntree described cases of water
intoxication in four dogs that received hypertonic fluid therapy and (two of them) developed
neurological manifestations [9]. Symptoms were, unfortunately, not correlated with any brain
morphological changes. The first suggestion of electrolyte disturbances and rate of correction of plasma
sodium as etiological factors is usually credited to Finlayson in 1973 or Tomlinson in 1976 [10,11], even
though Adams mentioned earlier in a conference abstract dehydration and electrolyte imbalance in
two cases of non-alcoholic CPM [12]. In 1982, Norenberg, who performed the autopsy of 12 ODS
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human cases with proven demyelinating lesions, underscored a strong link between the occurrence of
ODS and the correction of a hyponatremic condition [13]. By reviewing the medical history, he found
the natremia of all patients was raised by more than 20 mmol/L within three days. He also noted that
hyponatremic patients who were corrected using gradients less than 20 mmol/L or for a longer time
period did not develop symptoms of CPM. Several other studies supported the association between
chronic hyponatremia, its overcorrection and CPM [14,15]. Data from experimental studies performed
on dogs, rats and rabbits strengthened the fact that the rate of sodium correction after a hyponatremia
is one of the most correlated etiological factors [16–18]. Remarkably, the demyelinating lesions in dogs
appear in the exact same brain areas as reported in human cases, while the central pons is usually
spared in rats [19]. Despite these convincing studies in rats, dogs and rabbits, controversy has persisted
because a group of patients has remained that develops CPM without having undergone hyponatremia
or significant elevations in serum sodium, suggesting the involvement of a third variable.
4. Current Understanding of ODS Pathogenesis
4.1. Features of the Brain
Unlike other organs, the brain is tightly enclosed in the skull; this physical constraint necessitates
specific mechanisms of adaptation to prevent deleterious volume organ expansion. Volume changes are
particularly harmful to neurons, whose function is vulnerable to excessive cell swelling or shrinkage,
and millions of neural networks made of long and targeted neurites, whose function relies on the
integrity of their connectome. Volume alterations can greatly impact excitability, metabolism and
induce apoptosis in nervous cells. Therefore, the brain has developed osmo-regulatory mechanisms
allowing it to cope with a physiological range of osmotic fluctuations. In other words, changes
in extracellular osmolality will systematically lead to adaptation of brain cell osmolality. Change
in intracellular osmolality is an adaptive function and results from either an increase or a loss of
intracellular osmolytes. According to the paradigm that ODS develops into a slowly established
and severe hyponatremia that is too rapidly corrected, the following paragraphs decipher how the
pathophysiological mechanisms are currently understood.
4.2. Response to Hyponatremia
When hyponatremia settles, the brain cell intracellular compartment becomes progressively
hypertonic compared to the interstitial fluid. In theory, in the absence of any adaptation, extracellular
water would move freely across membranes from an area of low solute content into cells with a high
solute content, leading to cellular swelling. In the brain, glial cells have a particular role of water
handling and buffer the water movements in and out of the CNS. For instance, during hypotonic stress
due to water overload, glial cells selectively swell whereas neurons do not. Astrocytes express at high
levels of water permeable channels, AQP1 and AQP4, and are in close contact with the blood-brain
barrier, a crucial position for regulating influx and efflux of water or ions. The role of glial AQP4 in
brain water homeostasis has been characterized by the team of Verkman, who showed that AQP4−/−
mice had improved survival and less cerebral edema than wild-type mice in a model of brain edema
caused by acute water intoxication [20,21].
To counteract excessive cell swelling, glial cells lose inorganic osmolytes (first Na+ and Cl−, then
K+) over a period from few minutes to 24 h, which sustains an AQP4-mediated water efflux. This
adaptation is an energy-dependent phenomenon that requires the activation of Na-K-ATPases that first
expel Na+, followed by the extrusion of K+ and Cl− through K+ channels, the K+-Cl− co-transporter
and the volume-sensitive Cl− channel [22–26]. Brain edema would occur if the osmolyte depletion
rate is overridden, like during acute water intoxication.
It has been demonstrated that the maximum loss of intracellular cations (Na+ and K+) that
occurs during hyponatremic conditions is 18% compared to iso-osmotic conditions; hence, it has been
theoretically calculated that the corresponding natremia would be equal to 103 mmol/L. However,
Int. J. Mol. Sci. 2019, 20, 1124 4 of 18
hyponatremia below 100 mmol/L is not infrequent in human practice and not incompatible with
long-term survival, as evidenced in rodents, likely suggesting additional mechanisms of adaptation [27].
It was demonstrated that cells exposed to sustained hyponatremia were also losing organic osmolytes
over time [28]. This includes the extrusion of myoinisotol, betaine, creatine, taurine, glycine, aspartate,
glutamine and glutamate, with glutamine and taurine being the most severely depleted at the end of
such adaptative processes [29]. Interestingly, the efflux is delayed compared to inorganic osmolytes
(started over a day and completed within 48 h) [30]. Hence, its completion defines the empirical
threshold of acute (<48 h) versus chronic (>48 h) hyponatremia. Overall, the depletion of inorganic and
organic solutes drives the process of regulatory volume decrease and establishes an “adapted” osmotic
balance (shifted to hypotonicity) between the brain interstitium and the intracellular compartment.
As hyponatremia is a medical condition associated with significant morbidity (osteoporosis, gait
instability, fractures, deficits of attention) and increased mortality, EU and U.S. panel experts have
issued recommendations to properly manage the hyponatremic condition [31,32].
4.3. Following Correction of Hyponatremia
Things get complicated when the tenuous and previously reached osmotic equilibrium is
challenged by an abrupt correction of hyponatremia. If the correction occurs too rapidly, typically
using a bolus of hypertonic saline, osmolyte-depleted cells have to adapt towards a hypertonic
interstitial fluid, unless undergoing rapid cell shrinkage. The repumping of inorganic electrolytes
from the interstitial fluid can take place within minutes by activating ATP-dependent membrane ion
pumps, in the hope of restoring the intracellular inorganic ion content and osmotically driving water
influx. Although the rapid uptake of inorganic electrolytes helps to restore the size of shrunken cells,
it elevates the intracellular ionic concentration. Because high ionic strength can disturb the intracellular
folding of proteins or protein-protein associations, this condition is not sustainable in the long term
and cells must progressively organize a secondary response, based on the accumulation of organic
osmolytes. Once inorganic ion shifts have been exhausted, if the rise of tonicity is faster than the
rate at which organic osmolytes can be transported or de novo synthesized, the cell will ineluctably
shrink. Re-accumulation of intracellular organic osmolytes occurs at a slower rate and represents
a significant metabolic burden [30,33,34]. If, during the process of intracellular osmolyte recovery, there
is an imbalance between intracellular and extracellular osmolality, glial cells that sheath the synaptic
compartments or axonal processes will be subject to cell shrinkage, which may lead to irreversible
cellular damage, induction of apoptotic cascade and disruption of neuropil integrity [35,36]. In a few
cases of human ODS lesions resulting from solely hypernatremia, ODS is proposed to occur as a result
of hypertonic insult, in which the interstitial fluid becomes hypertonic faster than the rate at which the
brain cells can compensate by synthesizing or taking up osmolytes [2,37–39].
It remains unclear why there is such a regional patterning in CPM and EPM lesions, with the pons,
basal ganglia, mesencephalon or deep cortical layers more vulnerable than areas with higher myelin
content. In 1995, Lien and colleagues nicely correlated the fact that ODS-susceptible regions were those
that had a significant delayed recovery of organic osmolytes (glutamine, taurine, myoinositol, and
creatine), and subsequently those that will fail to optimally manage rapid changes in osmolality [40].
To date, the cell type accounting for the largest accumulation or depletion of those osmolytes is
unidentified. Furthermore, the fact that exogenous myoinositol administration improves survival and
reduces myelin loss in a rat model of ODS is a very strong indicator of the role of organic osmolytes [41].
4.4. Blood-Brain Barrier Disruption
The concept of BBB disruption is tempting but still debated. Brain endothelial cells are the
first cells that must face the rapid variations of plasma osmolality and whose barrier functions
could be compromised during regulatory volume processes. This hypothesis arose from autopsy
observations showing areas of greenish and yellowish discoloration in the basis pontis of CPM
patients, suggesting erythrocyte’s extravasation with subsequent hemoglobin degradation. Disruption
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of the BBB has been seen in experimental models of ODS [42–44]. The initiation of the opening,
the degree, the duration of disruption and its contribution to disease progression are matters of
speculation. Interestingly, the observation of the BBB opening is regionally correlated to brain areas
that are or will be undergoing myelin and oligodendrocyte loss. Rojiani et al. demonstrated leakage
of peroxidase from intravascular compartment and slightly increased brain water content as soon
as 3 h post-correction of chronic hyponatremia in rats [45]. This would suggest that the BBB is
compromised early. Ultrastructural analysis of endothelial cells evidenced high pinocytotic activity
and focal inter-endothelial fluid accumulation [46]. Perivascular astrocytic foot processes and neurites
were markedly swollen. All these morphological alterations tended to normalize at 48 h post-correction.
Using immunohistochemistry, Baker et al. showed extravasation of endogenous IgG and the C3d
split-fragment of activated complement (150 and 187 kDa, respectively) at 20 h and five days after rapid
correction of hyponatremia in rats, which further strengthens that large blood-borne molecules invade
the brain parenchyma [42,43]. Once endothelial cell junctions become permeable, small and large
plasma molecules such as serum complement, immunoglobulins, cytokines, and other inflammatory
mediators (e.g., nitric oxide released by damaged endothelial cells, etc.) have facilitated access to
brain parenchyma and would damage oligodendrocytes [47]. Using albumin extravasation and IgG,
Bouchat et al. showed that BBB breakdown was delayed compared to oligodendrocyte and astrocyte
damage in a mouse model of ODS [44]. To our best knowledge, all markers of BBB impairment that
were ever used in experimental works have a molecular weight equal or above 44 kDa (horseradish
peroxidase) [45]. Those tracers or plasma proteins extravasate in the case of significant BBB damage,
which does not mean that minimal alterations of the barrier might already occur during chronic
hyponatremia or immediately after the correction of hyponatremia; this should be investigated using
smaller intravascular tracers. Regardless of their size, blood protein extravasation favors water entry
through disrupted endothelial cell junctions and contributes to local vasogenic edema [46]. Remarkably,
no inflammatory cells (polymorphonuclear or lymphocytes) cross the BBB during the ODS course [48].
Although hemoglobin and degradation by-products were found in late ODS lesions of human autopsy
cases [5], red blood cells and hemosiderin deposits were never seen in the brain parenchyma of ODS
animal models [42–44]. It has been demonstrated that hemoglobin or other blood-borne molecules are
toxic to neurons and oligodendrocytes [49–54]. If BBB leaks, which more than likely are non-selective,
play a significant role in ODS pathology, the difficulty resides in explaining the selective loss of
oligodendrocytes with the relative sparing of neurons in the same demyelinated areas. An increase
in the permeability of the BBB has been well documented in other models of neurological disorders;
however, such a specific pattern of demyelination does not occur. These facts strongly imply that
the opening of BBB could count as an epiphenomenon, secondary to damage at the peri-vascular
astrocyte end-feet or to neuroinflammation, which is distinct from the primary osmotic insult. Finally,
glucocorticoid therapy mitigates the neurological and histopathological outcomes in experimental
paradigms [55–59]. It has been postulated that the effect observed was due to the prevention of the
BBB opening and/or restoration of its integrity.
5. From a Myelinating Oligodendrocyte Pathology
Mature oligodendrocytes arise from oligodendrocyte progenitors and neural stem cells and are
the cells dedicated to axon myelination in the CNS [60]. Myelin sheaths are a cellular expansion from
the oligodendrocytes, made of a vast number of membrane lipids and, to a lesser extent, of integral
proteins involved in the coherence of the multi-layered ensheathment [61]. The CNS myelin proteins
are proteolipid protein (PLP), myelin basic protein (MBP) and glycoproteins (such as myelin associated
glycoprotein (MAG)), and myelin oligodendrocyte protein (MOG)). PLP is the most abundant protein
in the central myelin. The highly lipid-rich myelin membrane acts primarily as an insulator for
axons, allowing high-velocity and energy-sparing electrical conduction. In mammals, myelination
is largely a postnatal event relevant to oligodendrocytes. After the completion of myelin biogenesis,
oligodendrocytes are still committed to preserving long-term myelin stability and functionality.
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Diseases affecting myelin development (hypomyelination or dysmyelination) or characterized by acute
or chronic myelin destruction (demyelination) lead to profound alterations of electrical conduction.
Neurological symptoms will be related to the anatomic site of demyelination. The term demyelination,
such as used in ODS, describes a loss of myelin with a relative preservation of axons [2]. Demyelination
results from disease affecting the myelin sheaths themselves or the oligodendrocytes that form them.
Although an axon that has been chronically or severely demyelinated tends to atrophy and degenerate,
demyelinating diseases exclude those in which axonal degeneration occurs first and degradation of
myelin is secondary (e.g., Wallerian degeneration).
During ODS, both myelin and oligodendrocytes degenerate. All the anatomopathological
features were fully described by the original authors upon microscopic observation of the first
cases of CPM [5,12]. Lesions included a range of histological alterations from mild intramyelinic
and intracellular edema to prominent swelling of the myelin sheaths, obvious myelinolysis with
oligodendrocyte degeneration; axon and neuronal cell bodies were preserved except at the very
epicenter of the lesions; lymphocytic infiltrates were absent, although myelin-loaded macrophages and
microglial cells were observed; no hallmark of liquefactive necrosis was observed. Subsequent reports
indicate that many ODS lesions are not demyelinating stricto sensu, given the concomitance of axonal
degeneration and myelin loss, especially in the epicenter of severe and long-established lesions [62–64].
Because of this singular pathological picture, the clinical identity of ODS is distinguishable from
brain hypoxia and from primary inflammatory demyelinating diseases [65]. In experimental models,
cell markers of oligodendrocytes such as CNPase (2′,3′-cyclic nucleotide-3′-phosphodiesterase), APC
(Adenomatous Polyposis Coli), O4 or Olig family proteins are used in immunohistochemistry to
evidence the cell-specific loss in demyelinating-prone areas [44,48,66]. In addition, staining (e.g.,
luxol fast blue, eriochrome R cyanin) and protein markers such as MBP, PLP, MOG, MAG are used
to characterize the demyelinating nature of the lesions, keeping in mind that histological stains
showed less specificity towards myelin subcomponents and that myelin proteins may be more or less
susceptible to rapid degradation following myelin attack [67,68].
Oligodendrocytes are privileged targets in a number of neurological diseases; a striking example
is hypoxic brain damage [69,70]. Apoptosis is often mentioned as the preferred mechanism of
cell death when it comes to oligodendrocyte death. Caspase-dependent activation of apoptosis
in oligodendrocytes results in rapid focal demyelination—within 24 h of cell loss [71]. Whether myelin
or oligodendrocyte is the primary target during ODS is still elusive, but there is some evidence for a
role of apoptosis in ODS. Using immunohistochemistry on human autopsy material, De Luca found
an imbalance between pro- and anti-apoptotic markers, with a shift toward increased expression
of apoptotic-related markers, death receptor 3, Bax, and Bak in glial cells [72]. Cellular stresses
contributing to oligodendroglial death are numerous: oxidative stress, excitotoxic insults, or volume
changes [69,73–76]. It is well established that the persistent physical shrinkage induced by hypertonic
stress leads to cell death in a variety of cell types. For example, it has been shown in thymocytes
lacking an efficient regulatory volume increase (RVI) response that hypertonic conditions result in
sustained cell shrinkage, leading to the activation of the apoptotic process, whereas other cell types that
have an RVI response were resistant to hypertonic-induced cell death [77]. In that respect, rat brains
exposed to systemic hypertonic conditions following mannitol infusion do not undergo massive cell
death but elicit an osmo-adaptative response, mostly in neurons and oligodendrocytes, as attested
by tonicity-induced expression of transcription factor TonEBP and increased expression of SNAT2,
a neutral amino acid transporter involved in their accumulation during volume recovery of shrunken
cells [78]. It is important to note that the magnitude of hypertonic challenge in this experimental
setting was to a large extent greater than the amplitude of correction of hyponatremia imposed in
a rat ODS model, meaning that hypertonic challenge per se is insufficient to induce oligodendrocyte
death. Alternatively, the authors of the study have hypothesized that chronic hyponatremia would
lead to the downregulation of signaling pathway regulating SNAT2 expression. As a result, during
the rapid correction of hyponatremia, no or delayed tonicity-induced expression of SNAT2 occurs
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in oligodendrocytes. Hence, the accumulation of amino acids is impaired and cannot counteract the
elevation of extracellular tonicity or intracellular ionic strength. Since oligodendrocytes probably
rely primarily on amino acid accumulation to recover their cell volume, they remain shrunken and
trigger activation of apoptotic pathways. Hypothetically, the other brain cells that do not rely on
SNAT2-mediated amino acid accumulation for osmo-adaptation are less affected.
In addition, oligodendrocyte death can be elicited by exposure to inflammatory cytokines during
acute or chronic neuroinflammation. In mice, local production of TNF- α by either astrocytes or
microglial cells potently and selectively induces p55TNF receptor-mediated oligodendrocyte apoptosis
and myelin vacuolation, even in a context of intact blood-brain barrier and the absence of immune cell
infiltration [79]. Numerous lines of evidence demonstrate the secretion of pro-inflammatory mediators
(TNF-α, IL-1α, IL-1β IL-6, iNOs) by astrocytes and microglia in experimental ODS models [66,80].
In such models, therapeutic interventions aiming at microglia inhibition [80–83] or antibody-based
TNF-α neutralization (Infliximab) [66] led to significant improvements in neurological signs and
less severe demyelination. If not the primary event in ODS, secondary inflammation with microglia
activation might exacerbate the oligodendrocyte injury inside the demyelinating lesions.
Intercellular connections between astrocytes and oligodendrocytes are vital for the proper
functioning of oligodendrocytes [84]. Gap junctions support the metabolic and electric coupling
of glial cells, affording the exchange of small molecules (<1.5kDa) such as water, ions (Ca2+), ATP or
glio-/neurotransmitters from one cell to another. Evidence shows that astrocyte gap junctions and
astrocyte proximity are essential for oligodendrocyte myelination activity [85,86]. This is illustrated
by the lethal phenotype of Cx47/Cx30 or Cx32/Cx43 dKO mice in which astrocyte-oligodendrocyte
communication is disturbed [87]. Interestingly, Cx47/Cx32 dKO mice, ablated for major oligodendrocyte
connexins, are not lethal but show abnormal myelin development, oligodendrocyte apoptosis and
axonal degeneration [88,89]. Finally, Cx30/Cx43 dKO mice (ablation of major astrocyte connexins)
develop white matter pathology with vacuolated oligodendrocytes and intramyelinic edema [90,91].
During experimental ODS, we and others have demonstrated an early loss of both astrocyte and
oligodendrocyte connexins, especially in ODS-susceptible brain regions [44,48]. For instance, Cx43
and Cx47 expression, as well as Cx30, is downregulated in the thalamus of an ODS mice model.
Dysregulation of major astrocyte-oligodendrocyte connexins could therefore participate in the local
demyelination process, and seems to concur with what has been observed in knockout mice.
The regional susceptibility of oligodendrocytes in ODS remains elusive. Most regions affected by
demyelination in ODS are made of grey-white matter juxtapositions, rather than pure white matter
tracts. It has been known for decades that oligodendrocytes populating grey matter are morphologically
different than those found in large fiber tracts. Originally, oligodendrocytes have been classified based
on morphological criteria [92–99]. Type I and II oligodendrocytes populate the grey matter and fine
white matter tracts, where they myelinate small caliber axons with short internode length. Type III and
IV oligodendrocytes myelinate large-diameter axons with longer internodes, forming myelin sheaths
whose thickness can reach 50 times that of type I/II oligodendrocytes [96,98,100]. The phenotype of
oligodendrocytes and the features of the myelin they build are largely dependent on the axons to which
they associate [101]. Adding to this structural heterogeneity is the recent description, in the mouse
brain,of 13 distinct Pdgfrα(+) oligodendrocyte populations based on their differential transcriptional
profiles [102].
6. Towards an Astrocyte Pathology
Astrocytes are indispensable for myelination; they regulate several aspects, from the trophic
support of oligodendrocytes to the myelinating activity of oligodendrocytes, and aid in removal of
myelin debris [85,103–110]. Several lines of evidence show that astrocytes are a prime susceptible cell
type during ODS. Astrocyte-specific pathological changes are summarized in Figure 1. The first clues
pointed to decreased expression of GFAP in the lesions of ODS rat model and in old demyelinated
lesions of human cases (Figure 1) [6]. This change in glial cell marker expression could be related to
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in vitro results already describing GFAP downregulation after cultured astrocytes had been exposed
to a cocktail of pro-inflammatory cytokines [111]. Solid evidence of astrocyte death was later produced
by Gankam-Kengné et al. in a rat ODS model. Using a modified TUNEL assay and gammaH2AX
immunolabeling, the authors observed DNA fragmentation and chromatin condensation, which
usually drive the early steps of apoptosis (Figure 1) [48,112]. This cell death was specifically detected
prior to myelin protein marker loss (i.e., MBP) and strikingly in most of the astrocytes of the future
demyelinated areas [48]. Later, the same authors strengthened the findings that the correction of
a chronic hyponatremia disturbs the apoptotic balance in the brain cells, by favoring the expression of
pro-apoptotic proteins Bax and Bim, while repressing anti-apoptotic proteins Bcl-XL and Bcl-2 [112].
Studying the temporal relationship between glial cell loss and demyelination in ODS mouse model,
Bouchat et al. found that astrocyte cell markers as well as oligodendrocyte cell marker loss also
preceded myelin loss [44]. Intriguingly, lesions in mice were not associated with any apoptotic markers
but rather with phosphoMLKL-immunoreactivity, a marker of necroptosis.
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Figure 1. Astrocytopathy during osmotic demyelination. Major changes observed in astrocytes of
demyelinating-prone regions include: downregulation of gap junctions (Cx30 and Cx43) [44,48],
dysregulation of aquaporin expression (AQP1 and AQP4) [113], ER stress and activation of
ER-associated degradation (ERAD) pathway [112], intracytoplasmic aggregates [112,114], swelling of
various organelles [44,46,114], loss of GFAP intermediate filaments [6,48], clasmatodendrosis [114],
nuclear condensation and upregulation of cell death markers [44,48,72,112].
Recently, Gankam-Kengné et al. showed in their experiments that astrocytes of the demyelinating-
prone regions accumulated large amount of insoluble, polyubiquitinated and aggregated proteins
(Figure 1) [112]. Singularly, those peculiar accumulations of protein materials were absent from
oligodendrocytes of the same brain regions and were seldom observed in neighboring neurons.
Concomitantly, the rapid correction of hyponatremia induced the expression of markers of endoplasmic
reticulum (ER) stress, the activation of ER-associated degradation pathway and autophagy. It was
shown 10 years ago in worms that acute loss of intracellular water following exposure to hypertonic
conditions causes a transient increase in the cytoplasmic ionic strength [115,116]. This ultimately
leads to improper protein folding, direct protein damage with loss of enzymatic activity, abnormal
protein-protein interaction and even protein aggregation. In this model, if osmotically challenged cells
have enough time to adapt, for instance along a slow establishment of hypertonicity, they are able to
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trigger intracellular pathways supporting clearance of abnormal proteins [115]. Moreover, intracellular
organic osmolytes act as molecular chaperones contributing to the stability and the solubility of
proteins, while certain osmolytes extrinsically help at protein folding [117]. Considering the osmolyte
depletion during the adaptation of hyponatremic conditions, it would not be astonishing if, when
faced with a relatively hypertonic environment during the correction of hyponatremia, brain cells
would be devoid of defense mechanisms against some protein misfolding [118].
Analyzing a mouse model of ODS at the ultrastructure, our group found evidence of serious
astrocyte injury. Astrocytes of demyelination-prone regions showed autolytic activities, with membrane
whorls and other complex cytoplasm figures exposing autophagocytosis, while huge whorls of astrocyte
end-feet self-excisions confirmed the process of clasmatodendrosis. The fragmentation of astrocyte
processes contributes to the loss of intercellular contacts and to the fragilization of the neuropil [114].
The perinuclear area as well as the most distal extensions of astrocytes showed swollen cytoplasm,
accompanied by endoplasm damage, mitochondria swelling and poor organelle content [114]. Still in the
mouse model, drastic downregulation of astrocytic gap junctions was seen as in the rat model [44,48,81]
(Figure 1) and occurred at the same time as the loss of other astrocyte cell markers (AQP4, S100b,
Aldh1L1). The restricted Cx43 loss in the thalamus was intriguing: thalamic astrocytes seemed to be
particularly sensitive to ODS whereas the striatum was entirely spared. Up to nine different subtypes of
astrocytes based on morphological criteria had been identified in the CNS. One could hypothesize that
this heterogeneity could explain their inconstant sensitiveness towards similar injurious stress. Beside,
ion channels, connexin, or cytoskeletal protein expression also present regional heterogeneity [119,120].
For instance, Griemsmann and co-authors combined analyses of mice with deletion of connexins
(Cx26−/−, Cx30−/−, Cx43−/−), gene and protein expression and showed that, in the thalamus,
the dominant connexin expressed is Cx30, with many cells lacking any expression of Cx43 [121].
In the hippocampus and neocortex, Cx43 is the predominantly expressed connexin. In conditional
KO mice, the deletion of Cx43 decreased the coupling in the hippocampus but not in the thalamus.
An analysis of Cx30 expression in the rat brain showed its widespread presence in the brainstem and
diencephalon [122]. Scattered cells in the hippocampal formation showed moderate intensity of labeling
for Cx30 and in telencephalic regions weak or no expression at all was found. While Cx30 and Cx43 are
usually co-localized, Cx30 is absent in the white matter. A study has shown that different classes of
astrocytes have clonal identity, suggesting that astrocyte heterogeneity is specified early during CNS
development [123]. Another study, however, showed that regionally distinct subsets of astrocytes receive
Hh signaling (through the Sonic Hedgehog receptor) and attenuation of Shh signaling in postnatal
astrocytes resulted in the upregulation of GFAP and cellular hypertrophy. These findings demonstrate
a role for neuron-derived Shh signaling in regulating specific populations of adult astrocytes [120,124].
Hence, regional ODS susceptibility might be explained by local neuronal-astrocyte crosstalk, differential
expression patterns and/or differential response to osmotic insult. In order to explore the astrocyte
region-specific vulnerability observed in ODS, Takeda and others isolated cells from the rat cerebral
cortex and from the cerebellum, then examined how extracellular sodium variations induce astrocyte
death and whether the response differed between the two populations of astrocytes [125]. In their study,
they showed that apoptosis could be induced in both cell populations by sustained exposure to high
extracellular sodium (306 mM) or by pharmacological voltage-gated Na+ channels opening. Intriguingly,
their findings showed that astrocytes from the cerebellum are more susceptible to extracellular sodium
alterations—mimicking the correction of hyposodic conditions—than cerebral astrocytes. The authors
hypothesized that this discrepancy between their in vitro data and what is observed in vivo ODS
models might be explained by a switch of cell phenotype when astrocytes are cultured.
During the correction of hyponatremia, glial cells are exposed to acute hyperosomolar stress,
leading to an immediate in-to-out water shift, followed by active Na+, K+, Cl- and amino acid re-uptake,
with later idiogenic osmoles synthesis. It is becoming more and more obvious that the intracellular
Na+ concentration ([Na+]i) plays a major role in astroglial homeostasis and signaling [126–128].
For instance, it has been measured that [Na+]i ranges from 10 to 17 mM in cultured astrocytes,
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which is remarkably high compared to cultured neurons (4 to 9 mM). Astrocytes undergo slight
fluctuations of this [Na+]i that are involved in the regulation of multiple homeostatic cascades.
Changes can elevate [Na+]i by 10–20 mM and propagate through the glial syncytium under the
form of Na+ waves. Astrocyte [Na+]i signals are elicited by the Na+ influx through ion channels
or Na+-dependent neurotransmitter transporters. Among those last, astroglial glutamate (EAATs)
and gamma-aminobutyric acid transporters (GATs) are of importance, because they are crucial for
maintaining a low synaptic neurotransmitter concentration. As a corollary, astrocyte [Na+]i influences
the uptake of glutamate and GABA at the synapse or from the extracellular spaces and thereby has
a direct impact on neuronal excitability. Increases in [Na+]i can impede re-uptake or even reverse the
transport activity. Astroglial GABA transporters are the most susceptible to [Na+]i fluctuations and
easily switch from a repumping mode to a reverse mode, with significant GABA release [129–131].
Moreover, changes in [Na+] can also affect the activity of glutamine synthetase, which further impacts
the glutamine-glutamate cycle [132]. Preliminary data obtained by our lab suggest that lesioned
astrocytes isolated from the ODS-susceptible region show a drastic downregulation of glutamate and
GABA transporters as well as glutamine synthetase at early time points following the correction of
hyponatremia (unpublished data). Impaired abilities to uptake or handle crucial neurotransmitters by
astrocytes in the cortex, basal ganglia network or thalamus might partially account for the neurological
symptomatology observed during ODS.
Astrocytes express both aquaporin-1 (AQP1) and aquaporin-4 (AQP4), highly permeable water
channels involved in brain volume homeostasis. Astroglial AQP4 is mainly expressed in the plasma
membrane of the perivascular end-feet, where it allows fast and efficient water shifts between
intracellular and extracellular fluids. In an experimental ODS model, astrocytopathy is strengthened
by the loss of AQP4 immunoreactivity in susceptible brain regions, well before demyelination and,
intriguingly, prior to GFAP downregulation (Figure 1) [81]. Autopsy study of six human brains with
CPM revealed that in four of the cases a loss of AQP1 and AQP4 was found within the demyelinating
lesions [113]. Unlike the rat ODS model, wherein GFAP is downregulated early in brain lesional
astrocytes, GFAP expression was preserved throughout the lesional astrocytes of CPM patients, despite
the astrocytes having downregulated AQP1 and AQP4 expression. This argues against the loss of
aquaporins’ immunoreactivity being secondary to the death of astrocytes. In the same study, although
fascicular oligodendrocytes within the lesions showed morphological features of apoptotic cells,
neighboring astrocytes did not show signs of cell death. Once again, this stresses that animal models
do not fully mimic human pathology and that, somehow, interspecies or inter-regional astrocytic
heterogeneity might explain these discrepancies.
7. Concluding Remarks
It is still not possible to predict the outcome and the recovery possibilities for patients undergoing
or having undergone ODS. While some patients fully recover and remyelinate, within several months,
there are patients who only partially recover neurologic functions, patient who do not recover at all
or even die [133–135]. Therapeutic interventions are nonexistent because early diagnosis remains
a challenge, as well as the detection of brain damage following an inadvertent rapid correction of
chronic hyponatremia. Clinical guidelines have been issued regarding the proper management
of hyponatremia, but no guidelines clearly define the most appropriate measures to undertake
once hyponatremia has been overcorrected. In animals, strategies using sodium relowering or
urea infusion decreased mortality rate and improved neurologic score. Currently, several human
case studies are showing improved neurological outcomes upon serum sodium relowering or urea
administration [136–138]. Scarce reports of therapy with intravenous immunoglobulin, plasma
exchange and thyrotropin-releasing hormone also suggest good neurological recovery in humans but
are difficult to interpret due to the small sample size [139,140]. Experimental animal models paved the
way for the current understanding of ODS etiopathogenesis and were useful for designing potentially
translatable therapeutic approaches in case of overcorrection of hyponatremia. Administration
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of minocycline [81–83], infliximab [66], dexamethasone [56,58] or lovastatin [80] showed reduced
neurological dysfunction correlated with less severe brain demyelination in animal models. Most of
these compounds target neuroinflammation or the activated microglia that undoubtedly contribute
to the disease by exacerbating myelinolysis and glial cell injury. In this regard, early detection of
glial stress during ODS would help with diagnosing brain damage and establishing an appropriate
clinical management. As demonstrated in human and animal models of ODS, both astrocytes and
oligodendrocytes suffer from osmotic stress, with astrocytes likely being among the first nervous cells
impacted. This is not surprising given the forward position of astrocytes and their role in regulating
water and ion fluxes at the gliovascular interface. When responding to osmotic stress, glial cells release
molecules that can serve as biomarkers for ODS progression. Hence, astrocyte-derived markers such
as AQP4 and S100β were assayed in the blood of ODS animal models and their concentration was
positively correlated with neurological impairments [48,81]. By using a panel of sensitive biomarkers
exploring oligodendrocytes’ and astrocytes’ viability, we should be able to detect the first signs of brain
damage, prior to the occurrence of demyelinating lesions.
The mechanisms of myelin loss in cell- or region-specific vulnerability towards osmotic insult
remain incompletely understood in ODS. Autopsy cases as well as experimental models suggest that
prominent degenerative changes in astrocytes precede oligodendrocytopathy and demyelination.
The dysfunction of astrocytes has been underestimated and overlooked, considering that brain
astrocytes regulate many homeostatic functions in coordination with those of oligodendrocytes and
neurons. It seems that, during ODS, the fate of oligodendrocytes is tightly linked to astrocytes’.
Surrounding neurons cope relatively well with the osmotic challenge, though myelinated axons
swell and sometimes degenerate in the lesion epicenter. The mechanism by which astrocytes and
oligodendrocytes locally trigger cell death upon the correction of hyponatremia remains unknown.
If hyponatremia status is a prerequisite for demyelination, one can speculate that chronic hyponatremia
downregulates the cell pathways involved in the response to relative hypertonicity. Interestingly,
experimental data showed that brain demyelination could be induced by hypernatremia using
a large osmotic gradient [141], which suggests that the response to cell shrinkage upon exposure to
hyperosmotic stimulus may be the key factor. If we could understand how glial cells from ODS-resistant
brain regions adapt to chronic hyponatremia and its correction and why they do not initiate cell death,
we would greatly advance the understanding of ODS pathology. The answer might come from
transcriptomic or metabolomic analysis at the single-cell level.
Hope also lies in the subgroup of patients that shows complete remyelination of the brain lesions
after an episode of ODS—or at least undetectable lesions using current brain imaging methods. Future
research should investigate how the endogenous repair abilities of the brain are activated, through
recruitment, stimulation and differentiation of glial-/oligodendrocyte-progenitor cells, and what lies
beneath the cause(s) of success or failure of remyelination. As demonstrated in other models of
demyelinating diseases, resident astrocytes and their reactive counterparts are possible sources of
oligodendrocyte precursors and may also significantly contribute to remyelination [142].
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